All In Biotech

NDA 021434 · Upjohn

Xanax Xr

Alprazolam · Oral · Benzodiazepine

Last checked: Nov 20, 2026Latest source record: Jan 13, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2003

Jan 17, 2003

Approved uses

1

Original approval plus efficacy supplements

Registered trials

103

8 Phase 3, 7 recruiting

FAERS reports

207,039

146,112 serious, 33,619 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS • Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation [see Warnings and Precautions (5.1) , Drug Interactions (7.1) ] . • The use of benzodiazepines, including alprazolam XR, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse...

What it is approved for

From the label in effect Feb 11, 2025.

Alprazolam XR is indicated for the treatment of panic disorder with or without agoraphobia, in adults. Alprazolam XR is a benzodiazepine indicated for the treatment of panic disorder with or without agoraphobia, in adults. ( 1 )

Mechanism: Alprazolam is a 1,4 benzodiazepine. Alprazolam exerts its effect for the treatment of panic disorder through binding to the benzodiazepine site of gamma‑aminobutyric acid-A (GABA A ) receptors in the brain and enhances GABA-mediated synaptic inhibition.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

4 products under this application
  • XANAX XR · ALPRAZOLAM 2MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XANAX XR · ALPRAZOLAM 0.5MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XANAX XR · ALPRAZOLAM 3MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB
  • XANAX XR · ALPRAZOLAM 1MG · TABLET, EXTENDED RELEASE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Alprazolam" as an intervention, any sponsor and status, largest first.

All 103 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective13,789
  • nausea13,196
  • fatigue12,296
  • drug abuse11,218
  • anxiety10,409
  • headache10,216
  • pain10,043
  • toxicity to various agents9,151
  • diarrhoea9,101
  • dyspnoea8,523
  • dizziness8,095
  • completed suicide7,665

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20043,043
20053,603
20063,463
20073,268
20084,048
20094,921
20107,823
20117,878
20129,792
20139,604
201410,368
201514,132
201614,600
201713,485
201814,883
201915,448
202014,606
202110,517
20229,670
20238,861
20248,543
20258,413
20266,063

Recalls

2 FDA enforcement reports for this application.

  • Mar 17, 2026 · Class II · Ongoing

    Failed Dissolution Specifications

  • Apr 28, 2022 · Class II · Terminated

    Failed Dissolution Specifications: low out-of-specification dissolution test results observed.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xanax XR (Alprazolam)

2024 spending

$222K

Beneficiaries

54

299 claims

Per beneficiary

$4,117

$11.62 per unit

View as table
YearSpending
2020$316,484
2021$390,402
2022$348,234
2023$294,924
2024$222,336

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 642 on PubMed

Sponsor: Upjohn

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.